MedTrace Logo

SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)

NCT06288893 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-03-04

No results posted yet for this study

Summary

Randomized, double-blind, placebo-controlled, multicenter phase II clinical study of SHEN211 tablets

Conditions

Interventions

DRUG

SHEN211 Tablets

SHEN211 tablets, participants will receive 330 mg (3 tablets) QD (once a day) on Day 1 and 110 mg (1 tablet) SHEN211 tablets QD orally on Days 2-5.

PROCEDURE

Placebo for SHEN211 Tablets

Placebo tablets, participants will receive 3 tablets QD (once daily) on Day 1 and 1 tablet QD orally on Days 2-5

Sponsors & Collaborators

  • JKT Biopharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hongzhou Lu, ph.D · Shenzhen Third People 's Hospital

  • Rui Song · Beijing Ditan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2024-08-01
Completion
2025-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06288893 on ClinicalTrials.gov